Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
Journal Article (Journal Article)
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.
Full Text
Duke Authors
Cited Authors
- Wyatt, CM; Chertow, GM
Published Date
- September 2016
Published In
Volume / Issue
- 90 / 3
Start / End Page
- 460 - 462
PubMed ID
- 27521103
Electronic International Standard Serial Number (EISSN)
- 1523-1755
Digital Object Identifier (DOI)
- 10.1016/j.kint.2016.06.021
Language
- eng
Conference Location
- United States